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background:  The DESolveTM Novolimus-Eluting Bioresorbable Coronary Scaffold System (BCSS) (Elixir Medical Corporation, 
Sunnyvale, CA) is a novel device that combines a PLLA-based scaffold coated with a potent antiproliferative sirolimus metabolite - 
Novolimus (5 mcg per mm of scaffold length).
methods:  126 pts w/ single de novo coronary lesions ≤14 mm in length located in a native coronary vessel 2.75 to 3.5 mm in diameter by 
online quantitative coronary angiography (QCA) were prospectively enrolled at 13 international sites between Nov/2011 and Jun/2012. Key 
exclusion criteria were left main or ostial location, bifurcation, total occlusion and heavy calcification. All pts were assigned for 6 months 
angiographic follow-up (FU). In addition, a subset of 19 pts included in a single site was scheduled for a second angiographic FU at 18 
months. Angiographic analyses were performed at an independent core laboratory. The primary efficacy endpoint was in-scaffold late 
lumen loss at 6 months.
results:  Overall, mean age was 62 yrs, 21% had diabetes, and 75% presented with stable angina. Baseline QCA demonstrated mean 
lesion length, reference diameter, and % diameter stenosis (DS) of 11.23 ± 3.75 mm, 3.00 ± 0.30 mm and 69.6±12.1%, respectively. 
Overall, the study scaffold was successfully implanted in 122 of 126 lesions. At postprocedure, % DS was 13.2 ± 7.5% and % acute recoil 
was 6.4%. At 6 angiographic follow-up (113 lesions or 93% of eligible patients), mean in-scaffold late lumen loss was 0.20 ± 0.32 mm. 
Considering only those with paired angiographic follow-up evaluation (n=19), mean in-scaffold late lumen loss at 6 and 18 months were 
0.25 ± 0.33 mm and 0.32 ± 0.36 mm, respectively (p=0.31), with a mean difference of 0.07 mm (95% confidence interval of -0.02 to 0.14).
Conclusion:  Overall, the DESolve BCSS demonstrated efficacy on the treatment of single de novo lesions, as demonstrated by the 
relatively low late lumen loss - a surrogate of neointimal hyperplasia, at 6 months follow-up. Serial angiographic evaluation at 6 and 18 
months demonstrated minimal change in late lumen loss, thus, suggests sustained efficacy overtime.
